EBS stock gains as first participant dosed in trial for Lassa virus vaccine (NYSE:EBS)

Emergent BioSolutions Inc. (NYSE:EBS), a company identified for its agreement producing do the job, announced Tuesday the dosing of the initially participant in its Period 1 trial for EBS-LASV, an experimental vaccine for Lassa virus infection. EBS shares attained ~9% in pre-market place buying and selling in reaction to the information.

The randomized, placebo-managed, dose-escalation examine will test the recombinant VSV-vectored vaccine applicant in virtually 36 healthy grownups in Ghana.

The Coalition for Epidemic Preparedness Innovations has partnered with EBS to carry out the plan.

Endemic in selected African countries, the Lassa virus can guide to an acute viral hemorrhagic sickness regarded as Lassa fever, wherever there is a major unmet have to have with no accepted vaccines or treatment plans.

“We are happy to deploy our merchandise progress and partnering abilities to deal with emerging infectious ailments like Lassa fever, for which there is presently no permitted vaccine or therapeutic, and to advance our pipeline for patients,” Emergent’s (EBS) SVP for R&D Kelly Warfield, remarked.

With organization shares down more than 50% this yr, Trying to get Alpha contributor Individual Trader noted in a bullish thesis very last thirty day period: “EBS inventory is now coming up from very long-time period assistance.”